Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Year range
1.
Journal of Zhejiang University. Science. B ; (12): 223-232, 2021.
Article in English | WPRIM | ID: wpr-880723

ABSTRACT

Gestational diabetes mellitus (GDM) is characterized by glycemia and insulin disorders. Bile acids (BAs) have emerged as vital signaling molecules in glucose metabolic regulation. BA change in GDM is still unclear, which exerts great significance to illustrate the change of BAs in GDM. GDM patients and normal pregnant women were enrolled during the oral glucose tolerance test (OGTT) screening period. Fasting serums were sampled for the measurement of BAs. BA metabolism profiles were analyzed in both pregnant women with GDM and those with normal glucose tolerance (NGT). Delivery characteristics, delivery gestational age, and infant birthweight were extracted from medical records. GDM patients presented distinctive features compared with NGT patients, including higher body mass index (BMI), elevated serum glucose concentration, raised insulin (both fasting and OGTT), and increased hemoglobin A1c (HbA1c) levels. Higher homeostasis model assessment of insulin resistance (HOMA-IR) and decreased β-cell compensation (i.e., oral disposition index (DI

2.
Chinese Journal of Biochemical Pharmaceutics ; (6): 100-102, 2017.
Article in Chinese | WPRIM | ID: wpr-511781

ABSTRACT

Objective To study the effect of Shengmai injection on the platelet parameters and CD4+CD25+cells in peripheral blood of patients with chronic lymphocytic leukemia,and to explore the optimal regimen for patients with chronic lymphocytic leukemia.Methods One hundred and twenty patients with chronic lymphocytic leukemia were enrolled in this study from January 2012 to December 2014.(D1),vincristine 4mg(d1),prednisone 60 mg/d(d1-5)were given to the CHOP regimen in the control group: cyclophosphamide 600 mg/m2(d1),doxorubicin 25 mg/m2(d12)28d a course of treatment,a total of 4 courses,the observation group of patients in the control group of patients treated on the basis of Shengmai injection,compared the two groups of patients with chemotherapy,platelet parameters and serum CD4+CD25+T cells and Th17 cells.Results After treatment,the PLT,MPV and PDW of the observation group were(215.4± 31.7),(9.5±2.5)and(16.9±2.4),respectively,which were significantly higher than those of the control group.The CD4+CD25+T cells in the observation group were(1.5±0.8)The total effective rate of the control group was 35.0%,the total effective rate was 35.0%,and the total effective rate of the control group was 35.0%.There were significant difference between the control group and the control group(P<0.05),The difference was statistically significant.Conclusion Shengmai injection combined with CHOP regimen in chronic lymphocytic leukemia patients can improve immune function,promote platelet growth,improve platelet clinical parameters,and help improve the efficiency of chemotherapy,compared with CHOP alone Program treatment is better,worthy of clinical application.

3.
Clinical Medicine of China ; (12): 523-526, 2017.
Article in Chinese | WPRIM | ID: wpr-613302

ABSTRACT

Objective To explore the clinical efficacy of anti-helicobacter pylori (HP) treatment on patients with type 2 diabetes mellitus and HP infection.Methods A total of 112 type 2 Diabetes patients were diagnosed with HP infection in Combine Traditional Chinese and Western Medicine Hospital of Taizhou from April 2012 to June 2016.These patients were divided into control and treatment group based on the preprandial blood glucose averages from lower to higher hierarchy.Thus,there were 56 patients in each of the two groups.The control group was given Motilium and Talcid for gastric symptoms in addition to anti-diabetes treatment,while the treatment was administered the same treatments as well as the quadruple anti-HP therapy (omeprazole,amoxicillin,clarithromycin and colloidal-bismuth-subcitrate,with Talcid stopped while colloidal-bismuth-subcitrate was administered).The anti-HP lasted for 14 days.The two groups were compared the gastric symptoms,the blood glucose levels,and the HbA1c one month after treatment.Half a year and one year post treatment,the two groups were compared the gastric mucus signs under gastroscopy.Results The improvement rates after treatment with the treatment group in abdominal pain,bloating,regurgitation,belching and diarrhea/constipation were 88.5% (23/26),83.3% (25/30),74.1% (20/27),83.9% (26/31),82.6% (19/23),respectively,and with the control group being 29.2%(7/24),32.1%(9/28),28%(7/25),30.3%(10/33),18.2% (4/22),respectively.The differences between the two groups were significant (x2=8.06,6.62,3.92,7.65,6.66,P<0.05 or P<0.01).The control group did not show significant changes in preprandial glucose levels,the glucose levels two hours post meals and the HbA1c(P>0.05) while the treatment group showed statistically significant changes(P<0.05 or P<0.01).The differences in the three indicators after treatment between the two groups were significant (t =4.07,7.85,4.16,P< 0.05).The Gastric mucus signs under gastroscopy showed improvements in both groups after treatment.The improvement rates with the treatment group were 86.2%(25/29),86.7% (13/15),77.8% (14/18),72.7% (8/11) respectively,with the control group being 36% (9/16),27.3% (3/11),13.3% (2/15),14.3% (1/7),respectively.The differences between the two groups were significant (x2 =6.71,4.12,4.38,3.85,P < 0.05 or P< 0.01).The effectiveness rate,which was based on combined improvements in gastric symptoms,glucose levels and gastric mucus signs,was 76.8% with the treatment group and 32.1% with the control group.The difference was statistically significant (x2 =6.78,P<0.01).Conclusion Anti-HP treatment can relieve the gastric symptoms,stabilize the glucose levels,and help to reverse the changed gastric mucus.All these can reduce the complications of the diabetes and improve the prognosis of the patients.

4.
Chinese Journal of Biochemical Pharmaceutics ; (6): 100-101,104, 2016.
Article in Chinese | WPRIM | ID: wpr-603389

ABSTRACT

Objective To investigate the effect of decitabine on serum platelet derived growth factor levels in patients with leukemia. Methods 120 cases of acute myeloid leukemia patients admitted to our hospital from January 2012 to December 2014 were selected as the study subjects.The control group was given CAG regimen: 1-14 d Seventh days of intravenous infusion of 20 mg/d aclarubicin, first to fourteen days subcutaneous injection of 10 mg/m2 , 1 times per 12 h, 1-13 d cytosine arabinosine days under the subcutaneous injection of granulocyte colony stimulating factor 300μg/d.The observation group was given to the west of the lake 25 mg/d, intravenous infusion, used for 5 days.The levels of platelet derived growth factor PDGF in the two groups were compared and the therapeutic effect.Results Before treatment, differences of PDGF in control group and observation group was no statistical significance.After treatment, PDGF in observation group was lower than control group ( P <0.05).The proportion of primary cells of bone marrow of two groups after treatment was lower than before treatment, and the observation group was more lower.Total effective rate of observation group was 55.0%,which was higher than that in control group(35.0%)(P<0.05).Conclusion Decitabine could reduce the level of of PDGF in patients with leukemia, and improve the total effective rate.

SELECTION OF CITATIONS
SEARCH DETAIL